Biopharma Industry Experts: Best Practices for Validated In-House NGS-Based Biosafety Workflows

Genedata Selector

Following the adoption of the ICH Q5A (R2) guideline by the FDA (USA) and EMA (Europe) in 2024, next-generation sequencing (NGS) has been recognized as a key alternative to traditional in vitro and in vivo assays for biosafety testing. In the “Industry Voices” podcast series, Genedata Selector interviewed biopharmaceutical industry experts about the best practices for implementing validated, NGS-based biosafety assays in-house.